These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. FOXP3 infiltrating lymphocyte density and PD-L1 expression in operable non-small cell lung carcinoma. Giatromanolaki A; Banham AH; Harris AL; Koukourakis MI Exp Lung Res; 2019; 45(3-4):76-83. PubMed ID: 31134811 [No Abstract] [Full Text] [Related]
3. Chemoradiotherapy efficacy is predicted by intra-tumour CD8+/FoxP3+ double positive T cell density in locally advanced N2 non-small-cell lung carcinoma. Boulle G; Velut Y; Mansuet-Lupo A; Gibault L; Blons H; Fournel L; Boni A; Cremer I; Wislez M; Duchatelle V; Trédaniel J; Hammond SA; Herbst R; Alifano M; Giraud P; Damotte D Eur J Cancer; 2020 Aug; 135():221-229. PubMed ID: 32610210 [TBL] [Abstract][Full Text] [Related]
4. Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Giatromanolaki A; Koukourakis MI; Sivridis E; Pastorek J; Wykoff CC; Gatter KC; Harris AL Cancer Res; 2001 Nov; 61(21):7992-8. PubMed ID: 11691824 [TBL] [Abstract][Full Text] [Related]
5. Expressions of CD8+TILs, PD-L1 and Foxp3+TILs in stage I NSCLC guiding adjuvant chemotherapy decisions. Teng F; Meng X; Wang X; Yuan J; Liu S; Mu D; Zhu H; Kong L; Yu J Oncotarget; 2016 Sep; 7(39):64318-64329. PubMed ID: 27602763 [TBL] [Abstract][Full Text] [Related]
6. Immune Microenvironment Differences Between Squamous and Non-squamous Non-small-cell Lung Cancer and Their Influence on the Prognosis. Meng X; Gao Y; Yang L; Jing H; Teng F; Huang Z; Xing L Clin Lung Cancer; 2019 Jan; 20(1):48-58. PubMed ID: 30341017 [TBL] [Abstract][Full Text] [Related]
7. Determination of poor prognostic immune features of tumour microenvironment in non-smoking patients with lung adenocarcinoma. Kinoshita T; Kudo-Saito C; Muramatsu R; Fujita T; Saito M; Nagumo H; Sakurai T; Noji S; Takahata E; Yaguchi T; Tsukamoto N; Hayashi Y; Kaseda K; Kamiyama I; Ohtsuka T; Tomizawa K; Shimoji M; Mitsudomi T; Asamura H; Kawakami Y Eur J Cancer; 2017 Nov; 86():15-27. PubMed ID: 28950145 [TBL] [Abstract][Full Text] [Related]
8. B7-H3 in combination with regulatory T cell is associated with tumor progression in primary human non-small cell lung cancer. Jin Y; Zhang P; Li J; Zhao J; Liu C; Yang F; Yang D; Gao A; Lin W; Ma X; Sun Y Int J Clin Exp Pathol; 2015; 8(11):13987-95. PubMed ID: 26823710 [TBL] [Abstract][Full Text] [Related]
9. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy. Tokito T; Azuma K; Kawahara A; Ishii H; Yamada K; Matsuo N; Kinoshita T; Mizukami N; Ono H; Kage M; Hoshino T Eur J Cancer; 2016 Mar; 55():7-14. PubMed ID: 26771872 [TBL] [Abstract][Full Text] [Related]
10. Programmed death-1 receptor (PD-1) and PD-ligand-1 (PD-L1) expression in non-small cell lung cancer and the immune-suppressive effect of anaerobic glycolysis. Giatromanolaki A; Koukourakis IM; Balaska K; Mitrakas AG; Harris AL; Koukourakis MI Med Oncol; 2019 Jul; 36(9):76. PubMed ID: 31342270 [TBL] [Abstract][Full Text] [Related]
11. [CD45RO⁺ Memory T Lymphocytes As A Candidate Marker for Non-small Cell Lung Cancer]. Tan Q; Li H; Yu M; Tang X; Tan J; Zhang S; Wang J Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):254-264. PubMed ID: 33910273 [TBL] [Abstract][Full Text] [Related]
12. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy. Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323 [TBL] [Abstract][Full Text] [Related]